$SRPT Oversold at Support Long

Sarepta Therapeutics, Inc.NASDAQ

Description

⋅ Oct 2, 2018 8:55 PM

SRPT RSI looking oversold on the daily chart, held trend line support well today. Expecting a bounce in the near/medium term.
Targeting $160 at least by next earnings release late October.

Note: Informational analysis, not investment advice.

Comments